shares of lyell immunopharma inc were higher in afterhours trading thursday after the company said the us food and drug administration cleared an investigational new drug application to initiate a phase 1 clinical trial for lyl845 lyell said the phase 1 trial will initially enroll patients with relapsed andor refractory metastatic or locally advanced melanoma and subsequently expand into nonsmall cell lung cancer and colorectal cancer initial data from the trial is expected to be presented in 2024 the company said at 419 pm et the companys shares had risen 1125 to 9 per share the stock finished the days regular session with a 202 gain closing at 809 per share